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Eur J Vasc Endovasc Surg (2010) 40, 139e140CORRESPONDENCEComment on “Advanced Carotid Plaque Imaging”Dear Editor,
We read with interest the review on advanced carotid
imaging techniques. Hermus and colleagues highlight the
predominant role of FDG-PET in imaging plaque inflamma-
tion in humans. We wish to point out however that FDG-PET
is limited by its spatial resolution (order of 4e5 mm). The
advent of integrated CT-PET technology should provide
automatic co-registration of areas of high signal on PET with
the structural information provided by CT. Another disad-
vantage of PET-FDG imaging is the associated radiation
burden, which limits the number of PET studies that patients
can have (2 in total), reducing its potential contribution in
assessing therapeutic interventions. It is also not formally
licensed to be used in diabetics by the Food & Drug Admin-
istration in the US, excluding an important group of vascu-
lopaths for imaging and potential risk stratification.
The authors briefly discuss the role of nanoparticles in
carotid plaque inflammation imaging and state that high
resolution MRI using nanoparticles has only been used in
animal studies (Table 3). This is not accurate. It has been
possible to image carotid plaque inflammation with Ultra
small Super-Paramagnetic Iron Oxide (USPIO) enhanced MRI
in humans.1 The use of a USPIO contrast medium e
Sinerem (Guerbet, Roissy, France), has allowed the direct
visualization of macrophage infiltration of carotid atheroma
in-vivo. Furthermore, Sinerem has been used as the first
targeted MR contrast medium to assess therapeutic
response in an interventional anti-inflammatory drug trial
in patients with carotid disease.2 Simultaneously it facili-
tated the enrichment of a trial population so that only
individuals with plaque inflammation were selected for
enrolment into the study.
We would be interested to hear the authors’ thoughts on
which technique holds the most promise as a biomarker in
inflammatory atheroma imaging.
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Response to Comment on “Advanced Carotid
Plaque Imaging”Dear Editor,
We would like to thank Tang and colleagues for their remarks
to our previous article and for the opportunity to highlightDOI of original article: 10.1016/j.ejvs.2010.03.033.
